MAM
DYN icon

Meeder Asset Management’s Dyne Therapeutics DYN Stock Holding History

Meeder Asset Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4
Closed – – 2191
2022
Q2 		$0 Hold
4
– – ﹤0.01% 2236
2022
Q1 		$0 Buy
+4
New +$34 ﹤0.01% 2365

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Meeder Asset Management's DYN Position: Q3 2022 in Review

Meeder Asset Management sold out of Dyne Therapeutics (DYN) in Q3 2022, closing a stake of 4 shares.

Meeder Asset Management first reported a position in DYN in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 102 funds tracked by Wall St. Rank hold DYN as of Q3 2022.

  • Meeder Asset Management reported no remaining Dyne Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Meeder Asset Management sold 4 Dyne Therapeutics shares in Q3 2022.
  • Meeder Asset Management first reported a position in Dyne Therapeutics in Q1 2022 and held it in 2 quarters.
  • Meeder Asset Management's Dyne Therapeutics position peaked at $0 in Q2 2022.
  • 102 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2022.

Based on Meeder Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.